Introduction {#s1}
============

Cryptococcosis, formerly known as torulosis, European blastomycosis, or Busse-Buschke disease, is caused by *Cryptococcus neoformans* (*C neoformans*). This species was first isolated from peach juice by Sanfelice in 1894 (Mitchell and Perfect, [@B66]; Jain et al., [@B48]). Cryptococcus is a spherical-to-oval, encapsulated, yeast-like fungus that is widespread in spoiled milk, soil, and bird droppings, especially pigeon excreta. *C neoformans* can be divided into *Cryptococcus neoformans* var neoformans (CNVN) and *Cryptococcus neoformans* var *gattii* (CNVG), both of which are pathogens in humans and animals. They were not considered different varieties until 1970, when CNVG was officially suggested as a new species based on mounting evidence discovered since the first CNVG report in 1896 (Speed and Dunt, [@B86]; Chaturvedi and Chaturvedi, [@B19]; Harris et al., [@B40]). In addition, an on-going CNVG outbreak originated in 1999 and reappeared in 2004 (Chaturvedi and Chaturvedi, [@B19]). The most affected organs are the lungs and central nervous system, but virtually any organ (e.g., the skin, joints, eyes, urinary tract, liver, prostate, myocardium, muscles, kidneys, and bone) can be involved through lymphangitic and hematogenous spread after inhaling fungal propagules. Skeletal cryptococcosis is rare. Furthermore, this disease can be divided into two types: skeletal cryptococcosis, which is an aspect of disseminated cryptococcosis, and primary skeletal cryptococcosis, which does not involve other tissues (Chleboun and Nade, [@B23]; Behrman et al., [@B8]; Wood and Miedzinski, [@B93]). Due to its low morbidity rate, little is known about this disease. Moreover, its basic clinical features, treatment, and prognosis have long perplexed clinicians. Serious consequences, including death, have occurred in certain patients (Singh and Xess, [@B83]). Therefore, a systematical retrospective analysis of skeletal cryptococcosis is crucial for understanding this disease. Unfortunately, however, almost all of the current studies regarding this disease have been presented as case reports (Ramkillawan et al., [@B76]; Zhou et al., [@B98]), which provides little and indirect insight for understanding of skeletal cryptococcosis. Thus, a systematic, retrospective analysis of all published cases of skeletal cryptococcosis reported between April 1977 and the present time was conducted to clarify its clinical features, treatments, and prognoses---all of which are critical issues for fully understanding this disease. Importantly, treatment and prognostic suggestions based on the analysis are provided.

Materials and methods {#s2}
=====================

Search strategy and selection criteria
--------------------------------------

A systematic online search was performed for cases reported over a 36-year period from April 1977 to the present time using PubMed, Medline, EBSCO, SpringerLink, Ovid, Highwire, ProQuest, and Wiley InterScience. We applied the following algorithm in both the medical subject heading (MeSH) and the search field. The MeSH terms "case reports" and "review" were combined with "Cryptococcus," "*Cryptococcus neoformans*," "osteomyelitis," or "immunocompromised host," and these MeSH terms were exploded when appropriate. Search terms such as "cryptococcosis," "skeletal," "bone," "joints," "skull," "arthritis," "disseminated," or "immunocompetent" were also combined with the MeSH terms to increase the number of relevant articles retrieved. Google Scholar was also searched, and the citations in each article were reviewed to identify additional references that were not retrieved during the primary search. Language restrictions were not applied, and two researchers independently conducted all searches.

"Disseminated skeletal cryptococcosis" was defined as an infection that involves two or more non-contiguous bone sites or an infection that involves one bone site associated with extra-skeletal sites; patients with soft tissue collections or abscesses adjacent to the involved bone were excluded (Wood and Miedzinski, [@B93]). "Classically immunodeficient conditions" were considered to include corticosteroid use, HIV infection, interleukin-2 deficiency, and T cell defects (Speed and Dunt, [@B86]; Yu et al., [@B94]). Patients with other underlying diseases that affect immune function, such as diabetes mellitus, tuberculosis and connective tissue disorders, were considered relatively immunocompromised. "Osteomyelitis" was defined based on a positive radiograph, bone scan, or histopathology (Harris et al., [@B40]). "Relapse" was defined as the recurrence of symptoms at the previous disease site and the rediscovery of viable cryptococci from a previously checked sterile body site after successful primary therapy (Perfect et al., [@B69]).

Data collection and analysis
----------------------------

The following information was retrospectively reviewed: patient sex, age, and epidemiological history; involved sites; clinical symptoms; underlying diseases; laboratory tests; radiological manifestations; and delays in diagnosis, treatment, follow-up assessment, and outcomes. Outcome was recorded as either response (i.e., resolution or improvement of all signs and symptoms, including microbiological and serological abnormalities and radiographic changes due to infection) or failure (i.e., deterioration of the patient\'s condition based on clinical features and radiographic abnormalities, ultimately resulting in death) (Kontoyiannis et al., [@B53]).

All cases were epidemiologically and clinically analyzed. The hosts were categorized as patients with immune abnormalities (including classically immunodeficient and relatively immunocompromised status) or as immunocompetent.

Statistical analyses
--------------------

Statistical analyses were performed using IBM SPSS 18.0 (IBM Corporation, Armonk, NY, USA). All continuous data were expressed as means ± standard deviations (means ± SDs), and comparisons were performed using One-Way ANOVAs. Categorical variables were compared using the χ^2^-test. All tests were two-tailed, and *p* \< 0.05 were considered significant.

Results {#s3}
=======

In total, 80 articles (including one written in Spanish \[case 50\] and 79 written in English) that described 89 patients were collected and analyzed retrospectively (Table [1](#T1){ref-type="table"}). Case 25 recorded only the affected site (orbit) and treatment (amphotericin \[AMB\] and ketoconazole); thus, this case was removed from the analysis due to unknown immune status.

###### 

**Summary of 89 cases of cryptococcosis of the bones and joints**.

  **Case no./References**                                          **Age/Sex**   **Bone or joint**                                              **ESR**    **Osteomyelitis**   **Dissemination**           **Underlying diseases**                                     **Treatment**                        **Outcome**   **Follow up**
  ---------------------------------------------------------------- ------------- -------------------------------------------------------------- ---------- ------------------- --------------------------- ----------------------------------------------------------- ------------------------------------ ------------- ---------------
  1/ Chleboun and Nade, [@B23]                                     43/M          Left tibia                                                     18         No                  No                          Sarcoidosis                                                 Surgery                              Failure       2 years
  2/ Chleboun and Nade, [@B23]                                     40/F          Left ulna                                                      44         No                  No                          Sarcoidosis                                                 Surgery                              Response      15 months
  3/ Chleboun and Nade, [@B23]                                     68/M          Left scapula                                                   92         Yes                 No                          Renal cyst                                                  Surgery                              Response      4 years
  AMB 1000 mg                                                                                                                                                                                                                                                                                                             
  4/ Chleboun and Nade, [@B23]                                     15/M          Left humerus                                                   NA         No                  No                          Normal                                                      AMB 395 mg                           Failure       2 years
  5/ Bryan, [@B13]                                                 26/M          T5                                                             NA         Yes                 No                          Normal                                                      AMB 2361 mg                          Response      1 years
  6/ Poliner et al., [@B72]                                        1.3/M         C2, C3                                                         Normal     Yes                 No                          Normal                                                      Surgery                              Response      16 months
  AMB 34 mg+5-FC 73 g                                                                                                                                                                                                                                                                                                     
  7/ Meredith et al., [@B65]                                       36/M          Right 2nd, 3rd ribs, C6, C7                                    NA         Yes                 Skin                        Normal                                                      AMB+5-FC                             Response      NA
  8/ Fialk et al., [@B28]                                          36/M          Left humerus, right femur, left iliac wing                     NA         No                  Lung, skin                  Normal                                                      Surgery+AMB 2 g                      Response      15 years
  9/ Fialk et al., [@B28]                                          9/M           Left tibia                                                     Normal     No                  No                          Normal                                                      Surgery+AMB 1500 mg                  Response      2 years
  10/ Fialk et al., [@B28]                                         18/M          Left tibia                                                     65         No                  No                          Normal                                                      Surgery+AMB 1500 mg                  Response      2 years
  11/ Galloway and Schochet, [@B30]                                71/M          Right frontal bone                                             NA         Yes                 No                          CLL                                                         AMB                                  Response      NA
  12/ Heenan and Dawkins, [@B43]                                   54/M          Right os calcis, left tibia, both ulnas                        NA         No                  Yes                         T-cell defect, multiple squamous cell tumors                Surgery                              Failure       25 months
  AMB+5-FC 2700 g                                                                                                                                                                                                                                                                                                         
  13/ Hammerschlag et al., [@B38]                                  11/F          Left femur                                                     40         Yes                 No                          Normal                                                      AMB 93 mg+5-FC                       Response      4 months
  14/ Shaff et al., [@B81]                                         19/F          Left calcaneus                                                 NA         Yes                 No                          TB, sarcoidosis, corticosteroid therapy                     Surgery+AMB+5-FC                     Response      NA
  15/ Amenta et al., [@B4]                                         33/M          Left femur                                                     Elevated   No                  No                          Normal                                                      Surgery+AMB                          NA            NA
  16/ Cash and Goodman, [@B17]                                     59/M          Bilateral middle and inner ear                                 NA         Yes                 CNS                         Chronic meningitis                                          AMB+5-FC                             Failure       
  17/ Perfect et al., [@B70]                                       46/F          NA (joint)                                                     NA         NA                  CNS, skin, blood            Renal transplantation, corticosteroid therapy               AMB+5-FC                             Failure       
  18/ Perfect et al., [@B70]                                       32/F          Polyarthritis                                                  NA         NA                  Retina, CNS, urine, blood   SLE, corticosteroid therapy                                 AMB                                  Failure       6 weeks
  19/ Perfect et al., [@B70]                                       47/M          Knee, ankle, wrist                                             NA         NA                  Blood                       Renal transplantation, corticosteroid therapy               AMB+5-FC                             Response      4 years
  20/ Bunning and Barth, [@B14]                                    54/M          Left knee                                                      NA         No                  Skin                        DM, HTN, cardiomyopathy                                     Surgery                              Response      22 months
  AMB+5-FC                                                                                                                                                                                                                                                                                                                
  21/ Reinig et al., [@B77]                                        10/F          Left parietal bone                                             NA         Yes                 No                          SLE, corticosteroid therapy                                 Surgery                              Failure       
  AMB+5-FC                                                                                                                                                                                                                                                                                                                
  22/ Matsushita and Suzuki, [@B61]                                50/M          T9, T10, T11                                                   30         Yes                 No                          DM, hepatitis, pulmonary silicosis                          Surgery×2, 5-FC 2202 g+AMB 1105 mg   Response      21 months
  23/ Levine et al., [@B56]                                        35/F          Left humerus                                                   30         Yes                 No                          Sarcoidosis                                                 Surgery+AMB                          Response      NA
  24/ Brand et al., [@B11]                                         26/F          Left sacroiliac joint, left ilium                              31         Yes                 Yes                         Haemolytic anemia, corticosteroid therapy                   Surgery+AMB+5-FC                     Response      NA
  25/ Gould and Gould, [@B34]                                      NA            Orbit                                                          NA         NA                  NA                          NA                                                          AMB+ketoconazole                     NA            NA
  26/ Zach and Penn, [@B95]                                        13/F          Right femur                                                    50         Yes                 No                          Normal                                                      AMB 1321 mg+5-FC                     Response      2 years
  27/ Ricciardi et al., [@B78]                                     37/M          Right knee                                                     NA         NA                  CNS, skin, blood            AIDS, IV drug abuse                                         AMB+5-FC                             Failure       
  28/ Baldwin et al., [@B7]                                        10/F          Right ilium                                                    111        Yes                 No                          Normal                                                      Surgery                              Response      NA
  AMB 504 mg+5-FC 224 g                                                                                                                                                                                                                                                                                                   
  29/ Govender et al., [@B35]                                      5/F           Left femur                                                     51         Yes                 No                          Normal                                                      Surgery                              Response      18 months
  30/ Govender et al., [@B35]                                      29/F          Right ilium                                                    60         No                  No                          Normal                                                      Surgery                              Response      18 months
  AMB+5-FC                                                                                                                                                                                                                                                                                                                
  31/ Stead et al., [@B87]                                         56/F          Left humerus and shoulder joint; right ischium and hip joint   NA         Yes                 Yes                         Normal                                                      Surgery+ketoconazole                 Response      1 years
  32/ Stead et al., [@B87]                                         4/M           Left elbow, right knee, right elbow                            NA         Yes                 Skin                        TB, kwashiorkor, chronic otitis                             Surgery                              Response      NA
  AMB+ketoconazole                                                                                                                                                                                                                                                                                                        
  33/ Sinnott and Holt, [@B84]                                     54/F          Right knee, metacarpophalangeal joint                          NA         No                  skin                        Renal transplantation, acute gout, corticosteroid therapy   AMB+5-FC                             Response      6 months
  34/ Lie et al., [@B57]                                           27/F          L2, L3, L4, L5                                                 Normal     No                  No                          Normal                                                      AMB+5-FC                             Response      2 months
  35/ Behrman et al., [@B8]                                        47/M          Right knee                                                     NA         Yes                 No                          TB                                                          Surgery+AMB                          Response      6 months
  36/ Kromminga et al., [@B54]                                     84/M          Rib, T10, T11, sacrum, femur                                   NA         Yes                 Yes                         DM, lung cancer                                             No                                   Failure       
  37/ Pirofski and Casadevall, [@B71]                              45/M          L1, L2, L3                                                     NA         Yes                 CNS                         AIDS, IV drug abuse, staphylococcal epidural abscess        Surgery+AMB                          Response      1 years
  38/ Dounis et al., [@B26]                                        55/F          Skull, patella, femur                                          NA         No                  CNS                         Normal                                                      Surgery+AMB +5-FC                    Response      7 years
  39/ Abdul-Karim et al., [@B1]                                    9/M           Left scapula                                                   Elevated   Yes                 No                          IL-2 deficiency                                             Surgery+AMB                          Response      NA
  40/ Ueda et al., [@B89]                                          58/M          Right tibia                                                    41         Yes                 No                          Normal                                                      Surgery×2+ketoconazole               Response      2 years
  41/ Sorensen et al., [@B85]                                      10/M          Left scapula                                                   NA         Yes                 No                          IL-2 deficiency                                             AMB+5-FC                             Response      4 years
  42/ Magid and Smith, [@B60]                                      54/F          Left clavicle                                                  NA         Yes                 No                          DM                                                          AMB+5-FC                             Response      10 months
  43/ Armonda et al., [@B6]                                        39/M          Left temporal bone                                             Elevated   Yes                 Skin                        Normal                                                      Surgery+AMB+5-FC                     Response      9 months
  44/ Gurevitz et al., [@B37]                                      67/F          L3                                                             70         Yes                 Lung                        Normal                                                      AMB 1000 mg+5-FC                     Response      2 years
  45/ Bosch et al., [@B10]                                         55/F          Right ischium, right hip                                       NA         Yes                 CNS                         DM                                                          Surgery                              Response      7 years
  AMB+5-FC+ketoconazole                                                                                                                                                                                                                                                                                                   
  46/ Glynn et al., [@B32]                                         52/F          L1, L2                                                         NA         No                  CNS                         Normal                                                      AMB+5-FC+ketoconazole                Response      7 years
  47/ Singh et al., [@B82]                                         56/M          Ankle                                                          NA         NA                  Skin, lung, blood           Liver transplantation, corticosteroid therapy               AMB+Flu+5-FC+ itraconazole           Response      6 months
  48/ Schmidt et al., [@B80]                                       53/F          Left femur, skull, left humerus, C5, C6                        NA         No                  Yes                         Normal                                                      AMB                                  Response      NA
  1095 mg+5-FC+Flu                                                                                                                                                                                                                                                                                                        
  Surgery                                                                                                                                                                                                                                                                                                                 
  49/ Wood and Miedzinski, [@B93]                                  49/M          Left temporal                                                  NA         No                  No                          Lymphopenia, hepatitis                                      Surgery                              Response      18 months
  AMB 300 mg+Flu                                                                                                                                                                                                                                                                                                          
  50/ Hummel et al., [@B45]                                        43/M          Left femur                                                     NA         Yes                 No                          Sarcoidosis, corticosteroid therapy                         Flu                                  Response      NA
  51/ Benard et al., [@B9]                                         57/M          Frontal bone, mandible                                         NA         No                  No                          Corticosteroid therapy                                      AMB+itraconazole                     Response      2 years
  52/ Kumlin et al., [@B55]                                        79/M          Right knee                                                     105        Yes                 No                          Lymphopenia                                                 AMB+5-FC                             Response      2 years
  53/ Mauri et al., [@B62]                                         41/M          Knee                                                           NA         NA                  CNS                         AIDS                                                        AMB 1500 mg+Flu                      Response      12 months
  54/ Liu, [@B59]                                                  60/M          Right humerus, right tibia                                     NA         Yes                 Yes                         TB, lymphadenitis                                           Surgery+AMB                          Failure       3 months
  55/ Raftopoulos et al., [@B75]                                   14/F          10th left rib                                                  22         Yes                 No                          Normal                                                      Surgery+AMB+Flu                      Response      7 months
  56/ Case Records of the Massachusetts General Hospital, [@B16]   55/M          Right tibia                                                    NA         Yes                 Lung, skin                  DM, renal transplantation, corticosteroid therapy           Surgery+Flu                          Response      NA
  57/ Jain et al., [@B50]                                          72/F          T6                                                             70         No                  lung                        DM, TB                                                      AMB+5-FC                             Response      5 years
  58/ Noh et al., [@B68]                                           21/F          Left sacrum                                                    NA         No                  CNS                         Hepatitis, corticosteroid therapy                           Surgery×2+AMB                        Response      3 years
  59/ Witte et al., [@B92]                                         68/M          Left humerus                                                   NA         Yes                 No                          DM                                                          NA                                   NA            NA
  60/ Prendiville et al., [@B73]                                   48/F          Sphenoid sinus, skull base                                     NA         Yes                 CNS                         Sinusitis, septicemia, corticosteroid therapy               Surgery×2 Flu+AMB                    Response      NA
  61/ Cook, [@B24]                                                 24/F          T1, T2, T3                                                     NA         Yes                 No                          Sarcoidosis                                                 Surgery+Flu+5-FC+AMB                 Response      16 months
  62/ Italiano et al., [@B46]                                      37/F          Left knee                                                      32         NA                  No                          Sarcoidosis, Sjogren\'s syndrome, corticosteroid therapy    AMB+5-FC                             Response      NA
  63/ Zanelli et al., [@B96]                                       27/F          Left ilium, left acetabulum                                    Elevated   Yes                 Muscles                     Lymphopenia                                                 Surgery                              Response      1 years
  AMB3 g+Flu+itraconazole                                                                                                                                                                                                                                                                                                 
  64/ Bruno et al., [@B12]                                         42/M          Left elbow joint, left wrist                                   NA         No                  tendon                      DM, renal transplantation, corticosteroid therapy           Surgery+Flu                          Response      6 months
  65/ Gupta et al., [@B36]                                         24/F          T1, T2, T3, 3rd rib                                            NA         NA                  Yes                         TB                                                          Surgery+AMB+5-FC                     Failure       2 weeks
  66/ Ching et al., [@B22]                                         17/F          Right posterior parietal                                       46         Yes                 CNS                         AML, corticosteroid therapy                                 Surgery+AMB+5-FC+Flu                 Response      NA
  67/ Wildstein et al., [@B91]                                     20/M          T12, L1, L2                                                    36         Yes                 No                          Sarcoidosis, corticosteroid therapy                         Flu                                  Response      6 months
  68/ Chang et al., [@B18]                                         22/M          Left 9th rib                                                   19         Yes                 Pleural                     Normal                                                      Surgery+AMB20 mg+Flu                 Response      12 months
  69/ Goldshteyn et al., [@B33]                                    19/F          Left humeral head                                              28         Yes                 Urine                       Sarcoidosis, corticosteroid therapy                         AMB+Flu                              Response      1 months
  70/ Hawkins and Flaherty, [@B42]                                 84/F          Left 3rd digit                                                 NA         Yes                 CNS                         BP, CHF, DJD, DM, hypothyroidism, corticosteroid therapy    Surgery×2 AMB+5-FC+Flu               Failure       2 months
  71/ Al-Tawfiq and Ghandour, [@B3]                                34/F          L4, L5                                                         89         Yes                 No                          TB                                                          Surgery+Flu                          Response      12 months
  72/ Amit et al., [@B5]                                           38/F          Frontoparietal joint                                           NA         Yes                 No                          Lymphopenia                                                 Surgery+Flu                          Response      NA
  73/ Saeed et al., [@B79]                                         54/F          Right frontal bone                                             NA         No                  No                          HTN                                                         Surgery+AMB+5-FC+Flu                 Response      6 weeks
  74/ Burton et al., [@B15]                                        35/M          Sternal notch, left elbow, left 5th and 6th ribs               NA         No                  Skin, CNS                   TB, AIDS                                                    Surgery+AMB+Flu                      Response      19 months
  75/ Geller et al., [@B31]                                        38/M          Left clavicle, sternoclavicular joint                          25         No                  Yes                         Testicular cancer, sarcoidosis                              Surgery+Flu                          Response      NA
  76/ Agadi et al., [@B2]                                          42/M          Right frontal bone                                             NA         Yes                 CNS                         DM, TB, lymphopenia, renal carcinoma                        Flu                                  Response      NA
  77/ Singh and Xess, [@B83]                                       29/F          L5, sternum                                                    NA         No                  Yes                         TB, pregnancy                                               AMB                                  Failure       
  78/ Houda et al., [@B44]                                         70/F          T8, T9, T10                                                    100        No                  CNS                         Normal                                                      Surgery+AMB+Flu                      Response      NA
  79/ McGuire et al., [@B63]                                       10/F          Left iliac crest                                               99         No                  No                          Normal                                                      Surgery×2+Flu                        Response      7 months
  80/ Jain et al., [@B49]                                          43/F          Proximal phalanx of middle finger                              35         Yes                 No                          Normal                                                      Surgery+AMB+Flu                      Response      6 months
  81/ Qadir et al., [@B74]                                         28/F          Left distal radius                                             26         Yes                 No                          Normal                                                      Flu                                  Response      12 weeks
  82/ Corral et al., [@B25][^\*^](#TN1){ref-type="table-fn"}       65/M          Right parietal bone                                            NA         Yes                 No                          Normal                                                      Surgery+AMB+Flu                      Response      2 months
  83/ Jou et al., [@B51]                                           50/M          Right femur, right 7th rib                                     NA         Yes                 Yes                         Normal                                                      Surgery+Flu                          Response      5 years
  84/ Zhang et al., [@B97]                                         57/F          Left scapula, left 6th rib                                     76         Yes                 Yes                         HTN                                                         AMB+5-FC+Flu                         Response      2 years
  85/ Jacobson et al., [@B47]                                      27/M          Right femur                                                    59         Yes                 No                          Normal                                                      Surgery+Flu                          Response      8 months
  86/ Flannery et al., [@B29]                                      65/F          T2                                                             34         Yes                 No                          DM                                                          AMB+5-FC+Flu                         Response      NA
  87/ Ramkillawan et al., [@B76]                                   56/M          Left humerus                                                   NA         Yes                 No                          Normal                                                      Surgery+AMB+Flu                      Response      NA
  88/ Jain et al., [@B48]                                          41/F          Sternum                                                        30         Yes                 No                          Normal                                                      Surgery+Flu+AMB+5-FC                 Response      1 years
  89/ Zhou et al., [@B98]                                          40/F          L4                                                             22         No                  No                          Rheumatoid arthritis, scleroderma                           Flu                                  Response      12 months

*NA, not available; 5-FC, 5-fluorocytosine; CLL, chronic lymphocytic leukemia; TB, tuberculosis; SLE, systemic lupus erythematosus; DM, diabetes mellitus; HTN, hypertension; IL-2, interleukin-2; Flu, fluconazole; AML, acute myeloid leukemia; BP, bullous pemphigoid; CHF, congestive heart failure; DJD, degenerative joint disease*.

*Variety identification taken*.

Sex and age
-----------

Forty-four (of 88, 50.0%) males and 44 (of 88, 50.0%) females were included. Their ages ranged from 16 months to 84 years with a mean (±SD) of 39.9 years (±19.6; Figure [1](#F1){ref-type="fig"}). Relatively immunocompromised hosts (*n* = 31, 48.8 ± 17.9 years) were older than immunocompetent hosts (*n* = 32, 33.9 ± 19.7 years; ANOVA, *p* = 0.002) and classically immunodeficient hosts (*n* = 25, 36.7 ± 18.5 years; ANOVA, *p* = 0.018); however, classically immunodeficient hosts were approximately the same age as the immunocompetent hosts (ANOVA, *p* = 0.587).

![**Pie chart of the 88 patients\' age**.](fmicb-05-00740-g0001){#F1}

Epidemiological histories
-------------------------

Thirteen (of 88, 14.8%) patients had epidemiological histories (Table [2](#T2){ref-type="table"}). The epidemiological histories of the patients with immune abnormalities (seven of 56, 12.5%) and those who were immunocompetent (six of 32, 18.8%) did not significantly differ (χ^2^-test, *p* = 0.629).

###### 

**Epidemiological histories of 13 patients**.

  **Case no./References**                                          **Age/Sex**   **Epidemiological histories**                                      **Immune status**
  ---------------------------------------------------------------- ------------- ------------------------------------------------------------------ --------------------------
  2/ Chleboun and Nade, [@B23]                                     40/F          Contact with soil (farmer)                                         Sarcoidosis
  52/ Kumlin et al., [@B55]                                        79/M          Contact with soil (farmer)                                         Lymphopenia
  56/ Case Records of the Massachusetts General Hospital, [@B16]   55/M          Contact with soil (farmer)                                         Renal transplantation
  82/ Corral et al., [@B25]                                        65/M          Contact with soil (agricultural worker), chronic trauma (1 year)   Immunocompetent
  87/ Ramkillawan et al., [@B76]                                   56/M          Contact with soil (agricultural worker)                            Immunocompetent
  38/ Dounis et al., [@B26]                                        55/F          Chronic trauma                                                     Immunocompetent
  62/ Italiano et al., [@B46]                                      37/F          Acute trauma                                                       Sjogren\'s syndrome
  68/ Wildstein et al., [@B91]                                     22/M          Chronic trauma (4 weeks)                                           Immunocompetent
  26/ Zach and Penn, [@B95]                                        13/F          Exposure to sea gull, chickens                                     Immunocompetent
  39/ Abdul-Karim et al., [@B1]                                    9/M           Exposure to sparrows droppings                                     Interleukin-2 deficiency
  49/ Singh and Xess, [@B83]                                       49/M          Exposure to pigeons                                                Lymphopenia
  60/ Prendiville et al., [@B73]                                   48/F          Exposure to a parakeet                                             Chronic sinusitis
  85/ Jacobson et al., [@B47]                                      27/M          Exposure to bird droppings                                         Immunocompetent

Involved sites
--------------

Regarding bone and joint infections, see Figures [2](#F2){ref-type="fig"}, [3A,B](#F3){ref-type="fig"}. Multiple site infections did not differ among the classically immunodeficient (10 of 25, 40.0%), relatively immunocompromised (13 of 29, 44.8%), and immunocompetent groups (10 of 32, 31.3%; χ^2^-test, *p* = 0.542). Extra-skeletal cryptococcosis was found in 34 patients (Figure [3C](#F3){ref-type="fig"}). The patients categorized as classically immunodeficient (16 of 25, 64.0%) were more likely to have extra-skeletal infections than were those categorized as relatively immunocompromised (10 of 31, 32.3%; χ^2^-test, *p* = 0.018) and immunocompetent (eight of 32, 25.0%; χ^2^-test, *p* = 0.003), whereas patients categorized as relatively immunocompromised or immunocompetent did not differ in this regard (χ^2^-test; *p* = 0.524). Excluding case 25, 42 (of 88, 47.7%) patients had disseminated cryptococcosis. The patients categorized as classically immunodeficient (17 of 25, 68.0%) were more likely to have disseminated cryptococcosis than were those categorized as immunocompetent (11 of 32, 33.4%; χ^2^-test; *p* = 0.012). Dissemination among the patients categorized as classically immunodeficient did not differ from that among those categorized as relatively immunocompromised (14 of 31, 45.2%; χ^2^-test; *p* = 0.087), nor did the dissemination among the patients categorized as relatively immunocompromised differ from that among those categorized as immunocompetent (χ^2^-test; *p* = 0.382).

![**Bones and joints involved (147 sites) in skeletal cryptococcal lesions**.](fmicb-05-00740-g0002){#F2}

![**Pie chart of patients\' involved bones **(A)**, joints **(B)** and extra-skeletal sites **(C)**: 123, 24, 34, respectively**.](fmicb-05-00740-g0003){#F3}

Clinical symptoms
-----------------

The predominant complaints included soft tissue swelling and pain, the duration of which ranged from acute admission to 3 years. Of the evaluable 86 patients (excluding cases 25, 41, and 50 whose data were not available), fever was observed in 18 (20.9%) patients, but body temperature measurements were only available in 12 of these patients (66.7%) and ranged from 37.4°C to 39.2°C (mean temperature = 38.35 ± 0.61°C).

Underlying diseases
-------------------

Of the 88 patients (excluding case 25), 25 (28.4%) were categorized as classically immunodeficient, 31 (35.2%) were relatively immunocompromised, and 32 (36.7%) were immunocompetent. Corticosteroid use (18 of 25, 72.0%) was the most common cause of classically immunodeficient status. Diabetes mellitus (nine of 31, 29.0%) followed by tuberculosis (seven of 31, 22.6%) and connective tissue disorders (five of 31, 16.1%) were the most common causes of the relatively immunocompromised status. Of the 32 patients in the immunocompetent group, 22 (68.8%) were described in articles published before 1999, and 10 (31.2%) were described in articles published after 2004. No immunocompetent patients were described between 1999 and 2004.

Laboratory tests
----------------

The erythrocyte sedimentation rate (ESR) was documented for 40 (of 89, 44.9%) patients. Thirty-seven (of 40, 92.5%) ESRs were elevated (i.e., \>20 mm/h for females and \>15 mm/h for males) for 24 (of 37, 64.9%) female patients and 13 (of 37, 35.1%) male patients. Among the 24 female patients, definite elevated ESRs were documented in 23 (of 24, 95.8%) patients (average, 52.0 mm/h ± 27.3), whereas among the 13 male patients, definite elevated ESRs were documented in 10 (of 13, 76.9%) patients (average, 49.0 mm/h ± 30.5).

The diagnostic specimens were most often obtained from open biopsies, followed by aspiration and incision and drainage (Table [3](#T3){ref-type="table"}). All 67 cases with fungal cultures showed positive results. Of the 53 histopathological analyses, the diagnostic specimens were obtained from open biopsies in 37 (69.8%) cases, aspiration in 13 (24.5%) cases, and incision and drainage in three (5.7%) cases; positive results were obtained for 21 (of 37, 56.8%) cases, seven (of 13, 53.8%) cases, and one (of three, 33.3%) case, respectively. Positive histopathological analyses showed foreign-body giant cells and capsulated yeast-like organisms. The capsule structure was stained using periodic acid Schiff (PAS) stain in 22 (of 29, 75.9%) patients, mucicarmine stain in 13 (of 29, 44.8%) patients, Gomori\'s Methenamine silver (GMS) stain in 18 (of 29, 62.1%) patients, Masson-Fontana silver stain in case 15, and colloidal iron techniques in case 23.

###### 

**Diagnostic modalities in 82 patients with skeletal cryptococcosis**.

  **Modality**            **No. of tests**   **Culture **n** (%)**   **Histopathological analysis **n** (%)**   **Both **n** (%)**
  ----------------------- ------------------ ----------------------- ------------------------------------------ --------------------
  Open biopsy             50                 13 (26.0)               10 (20.0)                                  27 (54.0)
  Aspiration              27                 14 (51.9)               5 (18.5)                                   8 (29.6)
  Incision and drainage   5                  2 (40.0)                0 (0)                                      3 (60/0)
  Total No.               82                 29 (35.4)               15 (18.3)                                  38 (46.3)

Only two patients with immunocompetent status (cases 44 and 82) had their strains successfully identified, using cultures on dihydroxyphenylalanine (DOPA) and canavanine glycine bromothymol (CGB) blue agars; both patients were infected with CNVN.

Radiological manifestations
---------------------------

Of the 89 patients, 77 (86.5%) had one or more radiological examinations of their affected bones. Sclerosis was observed in the relatively immunocompromised cases 23 and 45; periosteal reaction was described in 13 (of 76, 17.1%) patients. Subperiosteal new bone formation was noted in case 79 (immunocompetent), and irregular cortical destruction and extensive periosteal reaction was noted in case 59 (relatively immunocompromised).

Of the 80 evaluable patients, osteomyelitis was found in 51 (63.8%) patients. Case 41 was documented as having osteomyelitis, and the other 50 patients were diagnosed based on either a positive radiograph or bone scan; five (of 50, 10.0%) patients were also diagnosed based on a positive histopathology. The presence of osteomyelitis among patients categorized as classically immunodeficient (11 of 18, 61.1%), relatively immunocompromised (20 of 30, 66.7%), and immunocompetent (20 of 32, 62.5%) did not differ (χ^2^-test; *p* = 0.911).

Delays in diagnosis
-------------------

Of the 88 evaluable patients (excluding case 36, that was diagnosed post-mortem), delays in diagnosis occurred among 20 (of 88, 22.7%) patients. The delayed time of these 20 patients (documented in only 14 patients) ranged from 6 days to 10 months. In addition, 13 (of 20, 65.0%) patients were initially misdiagnosed (Table [4](#T4){ref-type="table"}), most commonly with tuberculosis (6 of 13, 46.2%) primarily occurring in the vertebrae (5 of 6, 83.4%). The location of the source of discomfort was not reported for the remaining 7 (of 20, 35.0%) patients.

###### 

**Misdiagnosis of 11 patients**.

  **Case no./References**            **Bone and joints**                       **Misdiagnosis**                  **Delay time**   **Treatment before diagnosis**    **Method of definite diagnosis**   **Treatment after diagnosis**   **Outcome**
  ---------------------------------- ----------------------------------------- --------------------------------- ---------------- --------------------------------- ---------------------------------- ------------------------------- -------------
  22/Matsushita and Suzuki, [@B61]   T9, T10, T11                              Metastatic cancer                 7 months         Irradiation ATT, immobilization   Histopathology                     Surgery, 5-FC+AMB               Response
  Tuberculosis                                                                                                                                                                                                                         
  28/Baldwin et al., [@B7]           Right ilium                               Musculoskeletal pain              6 weeks          Acetaminophen                     Histopathology culture             Surgery, AMB504 mg+5-FC224 g    Response
  29/Govender et al., [@B35]         Left femur                                Bacterial osteomyelitis           NA               Antibiotics immobilization        Culture                            Surgery                         Response
  32/Stead et al., [@B87]            Left elbow, right knee and right elbow    Tuberculosis                      18 weeks         ATT, antibiotics, physiotherapy   Culture                            Surgery AMB+ketoconazole        Response
  48/Schmidt et al., [@B80]          Left femur, skull, left humerus, C5, C6   Tuberculosis                      16 days          ATT                               Culture                            AMB+5-FC+Flu                    Response
  54/Liu, [@B59]                     Right humerus right tibia                 Bacterial infection               \>1 months       Incision and drainage             Histopathology culture             Surgery+AMB                     Failure
  57/Jain et al., [@B50]             T6                                        Tuberculosis                      \>3 months       ATT                               Histopathology culture             AMB+5-FC                        Response
  60/Prendiville et al., [@B73]      Sphenoid sinus, skull base                Tolosa-Hunt syndrome              \>2 months       Prednisone                        Histopathology culture             Surgery+Flu+AMB                 Response
  65/Gupta et al., [@B36]            T1, T2, T3                                Tuberculosis                      NA               ATT                               Histopathology                     Surgery                         Failure
  69/Goldshteyn et al., [@B33]       Left humeral head                         An avascular necrosis                              NSAIDs                            Culture                            AMB+Flu                         Response
  77/Agadi et al., [@B2]             L5, sternum                               Tuberculosis                      NA               ATT                               Histopathology culture             AMB                             Failure
  82/Corral et al., [@B25]           Right parietal bone                       Soft tissue infection             \>10 months      Antibiotics                       Histopathology culture             Surgery+AMB+Flu                 Response
  88/Jain et al., [@B48]             Sternal                                   Gastroesophageal reflux disease   NA               Antacids                          Histopathology culture             Surgery+Flu+AMB+5-FC            Response

*ATT, antituberculosis therapy; 5-FC, 5-fluorocytosine; AMB, amphotericin B; NA, not available; Flu, fluconazole; NSAIDs, nonsteroidal anti-inflammatory medications*.

Treatment, follow-up assessment, and outcomes
---------------------------------------------

Of the evaluable 87 patients (excluding patient 36 who did not receive any treatment and was diagnosed at autopsy as well as patient 59 whose treatment information was not available), 80 (of 87, 92.0%) patients received one treatment regimen and the other 7 (of 87, 8.0%) patients changed treatments because their symptoms became aggravated or recurred.

Of the 80 patients who received only one treatment regimen, 3 (of 80, 3.8%) patients received surgery alone, 32 (of 80, 40.0%) patients received medical treatment alone and 45 (of 80, 56.2%) patients received surgery in conjunction with medical treatment. Of the 3 patients that underwent surgery alone, 1 (of 3, 33.3%) patient died and 2 (of 3, 66.7%) patients responded. Of the 32 patients treated with medical treatment alone, 10 patients (31.3%) received monotherapy (AMB was the most commonly used treatment; 5 of 10, 50.0%) and three patients (30.0%) died. Twenty-two (of 32, 68.7%) patients received combined therapies (AMB plus 5-FC was the most commonly used treatment; 14 of 22, 36.4%), three of whom died (13.6%). Of the 45 patients treated with surgery and medical treatments, 18 patients (40.0%) underwent surgery and monotherapy (AMB was most commonly used; 10 of 18, 55.6%), one of whom died (5.6%). A total of 27 (of 45, 60.0%) patients underwent surgery combined with several medicines (AMB plus 5-FU was the most commonly used treatment; 11 of 27, 40.7%), four of whom died (14.8%).

In total, 68 patients responded to treatment, and 12 patients died (Table [5](#T5){ref-type="table"}). Improvements of the symptoms and the rclinical signs of all 68 patients who responded were observed. Only six of these patients\' (8.8%) ESRs were measured after treatment, all of which were normal or decreased. Only 13 (of 68, 19.1%) patients underwent serum cryptococcal antigen testing, and all of these patients showed reductions or undetectable levels. X-rays, CT, or MRI scans were obtained in 21 (of 68, 30.9%) patients, and all of them showed healing or resolution. Bone scans were performed in two (of 68, 2.9%) patients, and both of them presented reduced isotope uptake. Six of the 12 patients who received treatment but died were classically immunodeficient (50.0%), five were relatively immunocompromised (41.7%), and case 4 was immunocompetent (Table [6](#T6){ref-type="table"}). In addition, nine (of 12, 75.0%) patients presented with disseminated cryptococcosis. Only one of 12 patients\' deaths was directly caused by cryptococcosis (8.3%; case 65, relatively immunocompromised).

###### 

**Treatment of the 80 patients**.

  **Treatment**                              **Definite medical therapy**   **No. of patients**   **Outcome**   
  ------------------------------------------ ------------------------------ --------------------- ------------- -----------
  Surgery (*n* = 3)                                                         3                     2 (66.7)      1 (33.3)
  Medical treatment (*n* = 32)               AMB                            5                     2 (40.0)      3 (60.0)
                                             AMB+5-FC                       14                    11 (78.6)     3 (21.4)
                                             Flu                            5                     5 (100.0)     0 (0)
                                             AMB+Flu                        2                     2 (100.0)     0 (0)
                                             AMB+itraconazole               1                     1 (100.0)     0 (0)
                                             AMB+5-FC+Flu                   2                     2 (100.0)     0 (0)
                                             AMB+ketoconazole               1                     1 (100.0)     0 (0)
                                             AMB+5-FC+ketoconazole          1                     1 (100.0)     0 (0)
                                             AMB+5-FC+Flu+itraconazole      1                     1 (100.0)     0 (0)
                                                                            32                    26 (81.2)     6 (18.8)
  Surgery and medical treatment (*n* = 45)   AMB                            10                    9 (90.0)      1 (10.0)
                                             AMB+5-FC                       11                    8 (72.7)      3 (27.3)
                                             Flu                            6                     6 (100.0)     0 (0)
                                             AMB+Flu                        8                     8 (100.0)     0 (0)
                                             AMB+5-FC+Flu                   5                     4 (80.0)      1 (20.0)
                                             Ketoconazole                   2                     2 (100.0)     0 (0)
                                             AMB+ketoconazole               1                     1 (100.0)     0 (0)
                                             AMB+5-FC+ketoconazole          1                     1 (100.0)     0 (0)
                                             AMB+Flu+itraconazole           1                     1 (100.0)     0 (0)
                                                                            45                    40 (88.9)     5 (11.1)
  Total No.                                                                 80                    68 (85.0)     12 (15.0)

*AMB, amphotericin B; 5-FC, 5-fluorocytosine; Flu, fluconazole*.

###### 

**Twelve deceased patients**.

  **Case no./References**          **Age/Sex**   **Disseminated or not**     **Immune status**              **Treatment**            **Cause of death**
  -------------------------------- ------------- --------------------------- ------------------------------ ------------------------ -----------------------------------------------------
  1/ Chleboun and Nade, [@B23]     43/M          No                          Relatively immunocompromised   Surgery                  Unknown
  4/ Chleboun and Nade, [@B23]     15/M          No                          Immunocompetent                AMB395 mg                Tuberculous hepatitis and staphylococcal pneumonia
  12/ Heenan and Dawkins, [@B43]   54/M          Yes                         Classically immunodeficient    Surgery AMB+5-FC2700 g   Unknown
  16/ Cash and Goodman, [@B17]     59/M          CNS                         Relatively immunocompromised   AMB+5-FC                 Cardiorespiratory arrest on the 13th day of therapy
  17/ Perfect et al., [@B70]       46/F          CNS, skin, blood            Classically immunodeficient    AMB+5-FC                 Serratia septicemia
  18/ Perfect et al., [@B70]       32/F          Retina, CNS, urine, blood   Classically immunodeficient    AMB                      Unknown
  21/ Reinig et al., [@B77]        10/F          No                          Classically immunodeficient    Surgery AMB+5-FC         Respiratory failure
  27/ Ricciardi et al., [@B78]     37/M          CNS, skin, blood            Classically immunodeficient    AMB+5-FC                 Unknown
  54/ Liu, [@B59]                  60/M          Yes                         Relatively immunocompromised   Surgery AMB              Severe hepatic failure
  65/ Gupta et al., [@B36]         24/F          Yes                         Relatively immunocompromised   Surgery AMB+5-FC         Cryptococcosis
  70/ Goldshteyn et al., [@B33]    84/F          CNS                         Classically immunodeficient    Surgery×2 AMB+5-FC+Flu   Unknown
  77/ Agadi et al., [@B2]          29/F          Yes                         Relatively immunocompromised   AMB                      Cardiac failure

*AMB, amphotericin B; 5-FC, 5-fluorocytosine; Flu, fluconazole*.

Of the seven patients who changed treatment, symptom aggravation during primary treatment occurred among five (of seven, 71.4%) patients, one of whom (case 22, relatively immunocompromised) underwent an ESR examination that revealed an ESR increase from 30 mm/h to \>80 mm/h after the administration of 917 mg of AMB for 14 weeks. Symptoms recurred for case 7 (immunocompetent) and case 60 (relatively immunocompromised) after primary treatment, but neither met the criteria for relapse. Of these seven patients, one case (case 58) was categorized as classically immunodeficient, two were categorized as relatively immunocompromised, and the other four (57.1%) were categorized as immunocompetent. Three (of seven, 42.9%) patients presented with dissemination. All seven patients responded well to the subsequent treatment.

The follow-up time ranged between 2 weeks and 15 years (median = 13.5 months); half of all patients (30 of 60) were followed-up for less than 1 year, and the other half were followed-up for more than 1 year.

The factors associated with the overall skeletal cryptococcosis mortality rate, stratified by response to treatment, are listed in Table [7](#T7){ref-type="table"}. Dissemination was a risk factor the overall mortality rate (*p* = 0.041); the patient immune status was not a risk factor mortality (*p* = 0.056).

###### 

**Factors associated with overall skeletal cryptococcosis mortality (excluding cases 25, 36, and 59 and the 12 deceased patients)**.

  **Characteristics**         **Non-survival (%)**   **Survival (%)**   ***P*-value**
  --------------------------- ---------------------- ------------------ ---------------
  N                           67                     12                 
  Mean age                    39.2 ± 19.1            41.1 ± 21.1        0.752
  No. Male                    33 (49.3%)             5 (41.7%)          0.628
  Epidemiological histories   11 (16.4%)             0 (0)              0.289
  Multiple site infections    23 (34.3%)             6 (50.0%)          0.476
  Extra-skeletal infections   25 (37.3%)             6 (50.0%)          0.612
  Dissemination               28 (41.8%)             9 (75.0%)          0.034
  Immune abnormality          40 (59.7%)             11 (91.7%)         0.071
  Delay in diagnosis          14 (20.9%)             3 (25.0%)          1.000

Finally, to compare the mortality rates associated with different treatments, we analyzed 40 patients who were treated with AMB alone (2 of 5, 40.0%), AMB plus 5-FC (11 of 14, 78.6%), surgery combined with AMB (9 of 10, 90.0%), or surgery combined with AMB plus 5-FC (8 of 11, 72.7%); these cases were chosen because these three treatments (AMB, 5-FC and surgery) were utilized more often than other therapies. Specific information is listed in Table [8](#T8){ref-type="table"}. The mortality rates of the four treatment regimens did not differ (*p* = 0.229), and dissemination predicted mortality (*p* = 0.044).

###### 

**Factors associated with 40 patients treated with AMB alone, AMB plus 5-FU, surgery combined with AMB, or surgery combined with AMB plus 5-FU**.

  **Characteristics**                **Non-survival (%)**   **Survival (%)**   ***P*-value**
  ---------------------------------- ---------------------- ------------------ ---------------
  N                                  30                     10                 
  Mean age                           36.2 ± 22.4            36.6 ± 17.8        0.964
  No. Male                           16 (53.3%)             4 (40.0%)          0.465
  Epidemiological histories          5 (16.7%)              0 (0)              0.408
  Multiple site infections           8 (26.7%)              6 (60.0%)          0.126
  Extra-skeletal infections          11 (36.7%)             5 (50.0%)          0.709
  Dissemination                      11 (36.7%)             8 (80.0%)          0.044
  Immune abnormality                 16 (53.3%)             9 (90.0%)          0.090
  Delay in diagnosis                 7 (23.3%)              3 (30.0%)          1.000
  Treatment AMB                      2 (6.7%)               3 (30.0%)          0.229
                  AMB+5-FC           11 (36.7%)             3 (30.0%)          
                  surgery+AMB        9 (30.0%)              1 (10.0%)          
                  surgery+AMB+5-FC   8 (26.7%)              3 (30.0%)          

Discussion {#s4}
==========

Because knowledge regarding the clinical features, treatment, and prognosis of skeletal cryptococcosis is limited, this large-scale systematic analysis of previously reported skeletal cryptococcosis was conducted to better understand the disease.

Skeletal cryptococcosis affects both individuals who are immunocompetent and those with abnormal immunity (Behrman et al., [@B8]; Zhang et al., [@B97]). Our study revealed immune status to be an important risk factor for this infection, which is consistent with previous reports (Hawkins and Armstrong, [@B41]; Jacobson et al., [@B47]). Most of the patients with immune abnormalities included in this study had defects of cellular immunity such as those related to lymphoma, leukemia, sarcoidosis, and long-term steroid use. Cellular immunity defects might predispose patients to cryptococcal infection, which can lead to T cell abnormalities in hosts without other underlying diseases. This possibility suggests that T cell mediated immunity is the primary pathway for preventing cryptococcal infections (Meredith et al., [@B65]; Agadi et al., [@B2]; Jacobson et al., [@B47]). Thus, once a patient is suspected with cryptococcal infection, the evaluation of lymphocyte subsets, including counts and stimulation studies, should be routinely performed to specifically and sensitively reveal the patient immune status, as suggested by Wood and Miedzinski ([@B93]).

Since the introduction of highly active antiretroviral therapy (HAART) in 1995, the mortality rate associated with AIDS has dramatically decreased (Mitchell and Perfect, [@B66]). Subsequently, steroids are considered the leading cause of skeletal cryptococcosis because of their extensive use for both therapeutic and recreational purposes (Benard et al., [@B9]; Hummel et al., [@B45]). In addition, the incidence of chronic diseases such as diabetes mellitus and hypertension has increased (Jain et al., [@B50]; Witte et al., [@B92]; Bruno et al., [@B12]). The number of patients with cryptococcal disease and who are classified as immunocompetent has risen greatly since 2004 and is estimated to increase by 0.2 per million every year (Zhang et al., [@B97]; Jain et al., [@B48]; Zhou et al., [@B98]). This increase was most likely due to the CNVG outbreak that originated in 1999 and resurged in 2004 (Chaturvedi and Chaturvedi, [@B19]). However, determining the reasons why patients with immunocompetent statuses were not found between 1999 and 2004 is difficult. CNVN, which is ecologically widespread and exists in soil contaminated by pigeon excreta, is more common in immunocompromised patients with cell-mediated immune deficiencies, whereas CNVG, which is traditionally found in eucalyptus trees located in tropical and subtropical areas (Speed and Dunt, [@B86]; Chaturvedi and Chaturvedi, [@B19]; Harris et al., [@B40]) (the south-eastern region of China is the most common location (Chen et al., [@B20]; Negroni, [@B67]), affects immunocompetent hosts. Thus, it is essential for clinical microbiology laboratories to accurately differentiate CNVG from other forms of *C neoformans* to determine the final diagnosis and guide the initiation of or institute the appropriate treatment (Klein et al., [@B52]; Singh and Xess, [@B83]). Recently, a testing survey conducted by the New York State Department of Health indicated that only 5.0% of clinical laboratories were able to correctly identify CNVG (Klein et al., [@B52]). CNVN and CNVG are commonly differentiated by DOPA agar and CGB agar, where different colored reactions can be observed (Klein et al., [@B52]; Qadir et al., [@B74]). The results are often available within 48 h; CNVG produces a blue color, whereas CNVN fails to cause a color change. Furthermore, Klein and colleagues first used the specific method of D2 large ribosomal subunit region sequencing to identify CNVG (Klein et al., [@B52]). McTaggart and colleagues explored a cost-effective method called matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) (McTaggart et al., [@B64]). Feng X provided a rapid, simple, and reliable method using Singleplex PCR assay that is suitable for laboratory diagnoses and large-scale epidemiologic studies (Feng et al., [@B27]). Both strains were shown to have similar susceptibilities to antifungal drugs when tested *in vitro* in some reports (Chen et al., [@B21]; Thompson et al., [@B88]). The treatments for patients with disseminated disease due to CNVG are the same as those for CNVN.

Our study did not reveal a relationship between diagnosis and sex, which is consistent with previous reports (Behrman et al., [@B8]; Wood and Miedzinski, [@B93]; Zhou et al., [@B98]). However, Behrman and colleagues reported that 51.0% (20 of 39) patients were males in 1990 (Behrman et al., [@B8]), whereas Bruno and colleagues reported that 61.9% (13 of 21) patients were males in 2002 (Bruno et al., [@B12]); these findings might be due to the smaller number of reviewed cases in their studies. Cryptococcal infections occurred in all age groups, with a slight tendency toward for younger people to be affected (e.g., most patients were under 45 years of age). However, the patients with relatively immunocompromised statuses were elderly, which might be explained by the aforementioned leading cause of skeletal cryptococcosis (CNVN) and the fact that older patients are more likely to have chronic diseases.

Skeletal cryptococcosis is usually secondary to hematogenous migration from a primary pulmonary infection after inhaling microscopic, airborne fungal spores (especially after exposure to soil or poultry). These spores are a cause for cryptococcal infection (Armonda et al., [@B6]; Wood and Miedzinski, [@B93]). Direct inoculation during trauma is also possible (Chleboun and Nade, [@B23]; Dounis et al., [@B26]; Italiano et al., [@B46]). However, only 14.8% of the patients included in this review had contact with soil or pigeons or a history of trauma; incomplete patient histories might explain this finding. In addition, host immunity did not significantly affect their epidemiological histories. This result differs from that of Jacobson and colleagues, who reported that host immunity effectively excluded infection after initial exposure (Jacobson et al., [@B47]). This disparity might be due to the recent increase in patients with immunocompetent statuses. Other infectious pathways include direct inoculation through the skin during trauma and contiguous spread combined with the lower involvement of the lymphatic route (Zanelli et al., [@B96]).

Compared with most of the previous articles that reviewed skull cryptococcosis, articular cryptococcosis, or other bony cryptococcosis alone, such as in Chleboun and Nade\'s ([@B23]) study, we examined all types of involved sites (Chleboun and Nade, [@B23]). Any bone or joint can be affected, but the most common site was the vertebrae, which is consistent with Chleboun\'s report (Chleboun and Nade, [@B23]); the sufficient blood supply of the vertebrae might explain this finding. The second and third most common sites have changed from the pelvis and rib in 1977 to the skull and femur (Chleboun and Nade, [@B23]). The most common affected joint was the knee, which is consistent with the study by Bruno et al. ([@B12]). The involvement of multiple bones occurred more regularly in adjacent areas than discrete areas, which indicates the extension of local foci; this result is consistent with Behrman and colleagues\' study in 1990 (Behrman et al., [@B8]). Patients with classically immunodeficient statuses were most likely to have concurrent extra-skeletal involvement sites, and meningitis was the most common extra-skeletal infection. Overall, 47.7% of patients with (especially the classically immunodeficient status) or without immune abnormalities presented with dissemination, and these patients were more likely to show symptom aggravation, recurrence, or death.

The characteristic symptoms of skeletal cryptococcosis are pain and swelling (Chleboun and Nade, [@B23]; Behrman et al., [@B8]; Wood and Miedzinski, [@B93]). Fever, which is not a primary patient complaint (Behrman et al., [@B8]), was found in only 20.9% of evaluable patients comparable with a previous study, which reported a rate of 18.0% (Wood and Miedzinski, [@B93]). In addition, classic symptoms such as vomiting (Cash and Goodman, [@B17]; Agadi et al., [@B2]), blurred vision (Cash and Goodman, [@B17]; Prendiville et al., [@B73]; Ching et al., [@B22]), dizziness, seizure, diplopia, trismus (Cash and Goodman, [@B17]), limited motion (Bunning and Barth, [@B14]; Ricciardi et al., [@B78]; Sinnott and Holt, [@B84]), paralysis (Meredith et al., [@B65]; Gupta et al., [@B36]), muscle weakness, urinary retention (Gurevitz et al., [@B37]), and sciatica (Houda et al., [@B44]) can occur among patients with cryptococcal infections of specific sites; the location can assist in making the final diagnosis.

The ESR can be elevated to various levels when the infection is found in the bone, decline to normal when osseous lesions heal, and increase again when patients have an extensive relapse (Chleboun and Nade, [@B23]; Behrman et al., [@B8]; Wood and Miedzinski, [@B93]).

The diagnosis of skeletal cryptococcosis is primarily based on the examination of lesion specimens from aspiration, surgery, and open biopsies (Behrman et al., [@B8]; Wood and Miedzinski, [@B93]; Gupta et al., [@B36]). Aspiration was the most common method performed in our review, whereas Behrman and colleagues reported that open biopsy was the most commonly performed technique (Behrman et al., [@B8]); this discrepancy might be attributable to advancements in medical techniques since 1990. All of these methods have a similar diagnostic value. Thus, aspiration is recommended first given its increased convenience and minimal harm caused to the body; however, if aspiration specimens fail to yield diagnostic value, then open biopsy is recommended. All samples should be sent for culture, smear, and histology examinations (Wood and Miedzinski, [@B93]). Culture is the gold standard diagnosis (Wood and Miedzinski, [@B93]). After staining with India ink, the organism resembles cells with a halo due to a lack of capsule staining, and it is easily detected using specific PAS, mucicarmine, and GMS stains (although it is poorly stained by H & E). Urease-positive mucoid colonies are produced in cultures on SDA agar usually within 3--5 days (Mitchell and Perfect, [@B66]; Qadir et al., [@B74]; Jain et al., [@B48]). Currently available commercial methods for yeast identification, such as API 20 AUX (bioMerieux, Paris, France) and Vitek (bioMerieux), are used to identify the yeast-like organisms (Qadir et al., [@B74]; Zhou et al., [@B98]). Once the organisms are detected, identifying the strain is recommended as mentioned above.

Examinations for disseminated cryptococcosis should be performed after identification. Relevant examinations generally consist of the following procedures: lumbar puncture for antigen testing and culture, blood culture, urine culture, sputum culture, and skin lesion culture (Wood and Miedzinski, [@B93]). Recently, a marrow aspirate was considered in the diagnosis of disseminated cryptococcosis (Venkatachala et al., [@B90]). Testing for serum cryptococcal antigen using a latex agglutination test (LA), an enzyme immunoassay (EIA) or lateral flow assay (LFA) is useful for diagnosis given their sensitivity and specificity (Bruno et al., [@B12]; Lindsley et al., [@B58]; Hansen et al., [@B39]). However, serum cryptococcal antigen is not always positive even when infection is demonstrated via culture (Hawkins and Flaherty, [@B42]). CSF cryptococcal antigen testing is more highly sensitive and specific for meningitis than serum cryptococcal antigen testing (Hawkins and Flaherty, [@B42]).

The radiological findings of skeletal cryptococcus were non-specific (Chleboun and Nade, [@B23]; Behrman et al., [@B8]; Wood and Miedzinski, [@B93]); sclerosis or periosteal reaction, which are typical symptoms associated with tumors, were found in our study (Levine et al., [@B56]; Bosch et al., [@B10]; Witte et al., [@B92]; McGuire et al., [@B63]). Furthermore, patients with poor immune status were less likely to show radiological features of malignancy. The differential diagnoses based on radiological features included microbial infections, namely Staphylococcus aureus, Brucella, Actinomyces, tuberculosis, and neoplasms such as Ewing\'s sarcoma, osteogenic sarcoma, enchondroma, and giant cell tumor (Behrman et al., [@B8]; Witte et al., [@B92]). In addition, the diagnosis of osteomyelitis is commonly indicated based on radiological studies that are non-specific for *C neoformans* (Behrman et al., [@B8]), and our results showed that patients can contract osteomyelitis regardless of the presence of immune abnormalities. Radiological studies should be routinely performed because they assist the final diagnosis and can be used as a monitoring index to detect the efficacy of therapy based on radiological improvement, healing, or resolution.

The insidious course of this disease contributes to the delays in diagnosis (Bunning and Barth, [@B14]; Matsushita and Suzuki, [@B61]; Baldwin et al., [@B7]). Importantly, tuberculosis was the most common reason for misdiagnosis. Although our results indicated that delayed diagnosis did not contribute to a worse survival rate, clinicians must be alerted to this disease and identify it in a timely manner.

Except for the lungs ans CNS, no standardized treatment protocol exists for cryptococcal infection for specific body sites (Jain et al., [@B48]; Ramkillawan et al., [@B76]). For these sites, surgery in conjunction with antifungals, antifungals alone, or (rarely) surgery alone have been demonstrated to be effective. According to the Infectious Disease Society of America (IDSA), surgery, which effectively and rapidly eliminates the fungal burden and prevents the contiguous spread of infection (Chleboun and Nade, [@B23]; Govender et al., [@B35]; McGuire et al., [@B63]), should be performed to patients with persistent or refractory bone disease (Perfect et al., [@B69]). Surgery also provides physicians with the opportunity to obtain specimens for histological and microbiological examination to make a definitive diagnosis (Ramkillawan et al., [@B76]). The selection of antifungal agents and the duration of therapy depends on factors including disease severity, host immune status, the infection site, and therapeutic response (Qadir et al., [@B74]; Zhang et al., [@B97]). Systemic therapy consists of AMB, 5-FC, fluconazole, ketoconazole, or some combination therein (Bryan, [@B13]; Galloway and Schochet, [@B30]; Stead et al., [@B87]; Ueda et al., [@B89]; Perfect et al., [@B69]). Although, combination therapy with AMB and 5-FC (with or without surgery) did not outperform AMB alone (with or without surgery) in terms of improving the mortality rate (which might be due to the small number of cases), combined therapy is recommended. This result is contrary to previous reports (Bryan, [@B13]; Poliner et al., [@B72]; Shaff et al., [@B81]; Raftopoulos et al., [@B75]; Perfect et al., [@B69]) and might be due to the small number of cases reviewed here. Thus, combined therapy is recommended given the prevention of secondary drug resistance, the shorter duration of therapy, smaller total dosage, and the reduced likelihood of side effects (Bryan, [@B13]; Raftopoulos et al., [@B75]; Jain et al., [@B49]). The most common treatment is a combination of AMB and 5-FC, which can decrease the high nephro- and hepatotoxicity of AMB (Bruno et al., [@B12]). The lipid formulation of AMB is used in patients with renal impairments (Perfect et al., [@B69]). The IDSA indicates that 200-400 mg per day of oral fluconazole for 6--12 months is the treatment of choice for patients with immunocompetent status and non-meningeal, non-pulmonary cryptococcosis because of its significantly reduced toxicity (Agadi et al., [@B2]; Perfect et al., [@B69]; Qadir et al., [@B74]; Zhou et al., [@B98]). Several case reports published over the last decade have demonstrated the successful treatment of cryptococcal osteomyelitis using fluconazole alone (Hummel et al., [@B45]; Wildstein et al., [@B91]; Agadi et al., [@B2]; Qadir et al., [@B74]; Zhou et al., [@B98]). Patients with disseminated cryptococcosis had unfavorable outcomes in our study, and this result is consistent with previous reports (Behrman et al., [@B8]; Bruno et al., [@B12]; Hawkins and Flaherty, [@B42]). Combination induction therapy of AMB and 5-FC followed by consolidation and maintenance therapies with fluconazole are recommended for patients with disseminated cryptococcosis (Perfect et al., [@B69]; Zhang et al., [@B97]). Suppressive treatments for disseminated disease due to CNVG are the same as those for CNVN described above. The ultimate duration of therapy is unknown, but it should be based on clinical findings, ESRs, serum cryptococcal antigen levels, and radiological improvements (Goldshteyn et al., [@B33]; Zhang et al., [@B97]).

The outcomes of patients with disseminated cryptococcosis were unfavorable, and those of patients with or without immune abnormalities were similar; these findings differ from previous studies (Corral et al., [@B25]; Jou et al., [@B51]; Qadir et al., [@B74]; Jain et al., [@B48]). This disparity might be explained by the recent CNVG outbreak. The recurrence rate of skeletal cryptococcosis is low (Hawkins and Flaherty, [@B42]). However, unlike the successful treatment of cryptococcal meningoencephalitis (demonstrated via CSF culture) and that of pulmonary cryptococcosis (demonstrated via sputum culture or the specimens obtained during bronchoscopy) (Perfect et al., [@B69]), it is difficult to prove the success of primary therapy in skeletal cryptococcus. Hence, once cannot distinguish relapse from recurrence. Clinical and radiographical follow-up assessments, as well as serum cryptococcal antigens, should be monitored carefully. For the qualitative or quantitative detection of serum cryptococcal antigen, a latex agglutination test (LA), an enzyme immunoassay (EIA) or a LFA should be used, and LFA shows excellent overall agreement with EIA (Lindsley et al., [@B58]; Hansen et al., [@B39]). Once an abnormal manifestation occurs during the primary therapy, a larger total dosage is recommended. If the abnormal manifestation recurs, then susceptibility testing should be performed to formulate the best therapy by evaluating the changes in the minimum inhibitory concentration (MIC) of the recurrent isolates and original isolates (Perfect et al., [@B69]). Prednisone prescribed for other diseases should be tapered during skeletal cryptococcosis treatment, given the drug\'s effect on immunity (Noh et al., [@B68]).

Concluding remarks
==================

Skeletal cryptococcosis occurs in patients with immune abnormalities and even in those who are immunocompetent. An immune abnormality is a risk factor but it does not predict mortality. Likewise, neither immunocompetence nor immune abnormalities predicted the deaths caused by recent CNVG outbreaks. Patients with (especially classic immunodeficiencies) or without immune abnormalities present with dissemination, and these patients are more likely to have unfavorable prognoses. Clinicians must be alert to this disease and be able to identify the particular fungal strain. No standardized treatment protocol exists for skeletal cryptococcosis. Although, combination therapy with AMB and 5-FC (with or without surgery) did not outperform AMB alone (with or without surgery) in terms of improving the mortality rate (which might be due to the small number of cases reported), combined therapy is recommended. Given that our series was unable to collect all information (which led to difficulties in further elucidating this disease), creating a disease database of skeletal cryptococcosis is recommended.
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